Denali Advisors LLC lowered its holdings in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 6.1% during the 3rd quarter, Holdings reports. The firm owned 22,400 shares of the medical equipment provider’s stock after selling 1,450 shares during the quarter. Denali Advisors LLC’s holdings in Lantheus were worth $284,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of LNTH. Duncker Streett & Co. Inc. purchased a new stake in Lantheus during the second quarter valued at about $29,000. Federated Hermes Inc. bought a new stake in shares of Lantheus in the 2nd quarter valued at about $31,000. Mutual of America Capital Management LLC boosted its holdings in Lantheus by 91.2% during the 2nd quarter. Mutual of America Capital Management LLC now owns 3,216 shares of the medical equipment provider’s stock valued at $46,000 after acquiring an additional 1,534 shares during the period. PNC Financial Services Group Inc. grew its position in Lantheus by 45.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,271 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 1,026 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Lantheus by 49.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,135 shares of the medical equipment provider’s stock worth $73,000 after purchasing an additional 1,697 shares during the period. Institutional investors own 85.66% of the company’s stock.

In other news, CEO Mary Anne Heino sold 3,000 shares of Lantheus stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $16.02, for a total transaction of $48,060.00. Following the sale, the chief executive officer now owns 604,793 shares of the company’s stock, valued at approximately $9,688,783.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.08% of the company’s stock.

Several brokerages have recently issued reports on LNTH. Jefferies Financial Group initiated coverage on shares of Lantheus in a report on Monday, June 29th. They issued a “buy” rating and a $29.00 target price on the stock. BidaskClub raised shares of Lantheus from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Zacks Investment Research upgraded shares of Lantheus from a “sell” rating to a “hold” rating in a research report on Friday, July 10th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $29.00.

NASDAQ LNTH traded up $0.10 on Friday, hitting $13.35. The company’s stock had a trading volume of 392,595 shares, compared to its average volume of 528,812. The firm has a market cap of $891.95 million, a P/E ratio of 44.50 and a beta of 0.96. Lantheus Holdings Inc has a 52-week low of $8.67 and a 52-week high of $21.84. The company’s 50-day simple moving average is $12.96 and its 200 day simple moving average is $13.41. The company has a current ratio of 2.37, a quick ratio of 1.91 and a debt-to-equity ratio of 0.41.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, July 30th. The medical equipment provider reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.08. The company had revenue of $66.01 million during the quarter, compared to analyst estimates of $55.77 million. Lantheus had a return on equity of 20.57% and a net margin of 3.51%. The firm’s revenue was down 23.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.27 earnings per share. On average, research analysts forecast that Lantheus Holdings Inc will post 0.21 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Further Reading: Dead Cat Bounce

Want to see what other hedge funds are holding LNTH? Visit to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.